Introduction
Alzheimer's disease (AD) and frontotemporal lobar degeneration (FTLD) are the two most common causes for early-onset dementia (EOD) [1] . Approximately 35-60% of the early-onset AD (EOAD) and over 40% of the FTLD patients have at least one affected first-degree relative in their family and approximately 10% of these patients present the pattern of autosomal dominant inheritance [2, 3] . The patient's probability of having AD caused by a pathogenic mutation increases if the his or her family presents AD in several generations and the age at the onset is very early (under 55 years) [4] . Mutations in amyloid precursor protein (APP), presenilin-1 (PSEN1) and presenilin-2 (PSEN2) genes account for 5-10% of EOAD while at least 20% of the EOAD patients have been estimated to display autosomal dominant inheritance of a still unknown genetic background [2] . To date, over 50 pathogenic mutations in APP, over 200 mutations in PSEN1 and over 30 mutations in PSEN2 genes are known to cause EOAD [2] .
The C9orf72 hexanucleotide repeat expansion or MAPT and GRN mutations underlie the majority of the familial FTLD [5, 6] . In Finland, the prevalence of the C9orf72 repeat expansion is exceptionally high [7] , whereas MAPT and GRN mutations associated with FTLD or PSEN1, PSEN2 and APP mutations associated with AD have been found to be very rare [8] [9] [10] .
The apolipoprotein E (APOE4) ε4 allele is the main genetic risk factor for both EOAD and late onset AD (LOAD) [2] . However, APOE4 has not been indicated to elevate the risk for FTLD.
Recent genome-wide association studies (GWAS) and next generation sequencing studies (NGS) have so far identified over 20 other AD risk genes and genetic loci [11] . The genetic risk factors identified for LOAD have been suggested to modulate the risk for EOAD as well [12, 13] . Previous NGS studies have shown that EOD patients are more often associated with multiple rare variants or risk alleles than LOAD patients or healthy controls [12] .
The aim of this study was to evaluate the genetic background of a Finnish EOD cohort by analysing genes associated with AD and FTLD using targeted next generation exome sequencing.
Patients and methods
The study population consisted of 39 patients with EOD diagnosed at two memory outpatient clinics in Finland (Oulu University and Kuopio University Hospitals). The inclusion criteria of the patients were 1) early onset of the disorder (before 65 years) and 2) at least one patient with dementia in their family or 3) atypical or rapidly progressive course of the disease. All the patients were examined and diagnosed by an experienced neurologist specialized in memory disorders. The diagnoses were made according to the current prevailing diagnostic criteria for each disease. Also re-evaluation of the diagnoses [14] [15] [16] [17] for this study was made by experienced neurologists. In total, 29 patients were diagnosed with AD, nine with FTLD and one with progressive supranuclear paresis. Three of the FTLD patients had also motor neuron disease. In our cohort, 44% (n=17) patients had at least one first-degree relative with dementia or cognitive decline and 51% (n=20) patients had a family history of cognitive decline in at least in second-degree relatives.
The mean age at onset was 54.8 years (range 39-65) and the mean age at diagnosis was 57.6 years (range 40-67). The patients carrying the C9orf72 repeat expansion were excluded from the study. Three patients were carriers of the APOE4 allele and they all had APOE genotype E3/E4. The study was performed according to the principles of the Declaration of Helsinki.
Written informed consent was obtained from all the patients or their caregivers. The research protocol was approved by the ethic committees of the Northern Ostrobothnia hospital district and by the Northern Savo hospital district. DNA was extracted from the blood samples by standard methods. DNA purification was done with Qiagen purification Kit (Qiagen, Hilden, Germany) according to the original protocol. The repeat-primed polymerase chain reaction assay (RP-PCR) was used to indicate the presence or absence of the C9orf72 repeat expansion [18] . Targeted PRNP and BIN1) were selected for detailed investigation from the targeted panel of 258 genes and 22 additional genes. An in-house developed analysis pipeline was used for the evaluation of raw fastq files generated by the MiSeq sequencer. The data was manually screened to find exonic single-nucleotide mutations that cause a protein change. The recognized mutations were categorized as pathogenic, non-pathogenic and possible new variants or risk variants according to the previous literature and databases [19] . The relevant findings were confirmed by Sanger sequencing with ABI3500xL Genetic Analyzer (Applied Biosystems Inc, Foster City, USA, California). Primers and reaction conditions are available upon request. Exon-intron boundaries of APP, PSEN1, PSEN2, MAPT, GRN, VCP, CHMP2B, FUS and TARDBP genes were manually screened to find splice site mutations.
Results
Two patients (5.1%) were found to harbor previously reported pathogenic mutations p.His163Arg in PSEN1 or p.Arg406Trp in MAPT. In addition, a PSEN2 p.Arg71Trp mutation with an unclear pathogenic nature [20] was detected in a neuropathologically confirmed AD patient.
We also identified non-pathogenic variants GRN p.Arg433Trp, PSEN1 p.Glu318Gly, MAPT p.Gln230Arg and MAPT p.Tyr441His in our cohort. Furthermore, we detected three AD risk variants in TREM2, UBQLN2 and BIN1 genes. Two variants in TMEM106B gene which have previously been reported to be associated with mainly FTD were detected in both AD and FTLD patients (Table 1) . Moreover, we found one intronic splice-site mutation in APP which has unknown effect on protein code (Table 1. ). All the patients were heterozygous carriers of the mutations or variants. The patient carrying the TREM2 variant had APOE genotype E3/E4.
Phenotypes of the patients carrying the pathogenic mutations PSEN1 p.His163Arg (c.A488G)
A 39-year-old woman referred to a neurologist due to rapidly progressive cognitive decline. A bipolar mood disorder had been diagnosed in her early twenties. In neurological examination, the patient presented slight postural tremor in her upper limbs, clumsy movements and myoclonic jerks. In addition, tardive dyskinesia/tic-symptoms were observed around her mouth as well as vocal tics. The patient was euphoric, and she presented behavioral disinhibition.
Magnetic resonance imaging (MRI) of the brain was normal. In the cerebrospinal fluid (CSF) examination, phosphorylated tau was elevated, 252 pg/ml (normal concentration under 70 pg/ml), while beta-amyloid-42 (Aβ42) was relatively low, 582 pg/ml (normal concentration over 500 pg/ml). Neuropsychological examination revealed severe cognitive decline and the patient was diagnosed to have AD. At the age of 44 years she had an epileptic seizure and a computed tomography (CT) of the brain was done showing severe central atrophy and Scheltens grade 2 hippocampal atrophy [21] . Slowness and central spikes, but no epileptic bursts were found in the electroencephalography. At the age of 45 years she was bedridden and unable to speak. The patient died at the age of 46 years, but no autopsy was done. Her mother and sister as well as many of the mother´s siblings had been diagnosed with psychiatric syndromes. The patient's mother had also Parkinson's disease and she had died at the age of 70 years.
MAPT p.Arg406Trp (c.C1216T)
A 52-year-old woman presented subjective memory disturbances. In addition, her behaviour was impulsive and she had fluctuating mood changes. Neuropsychological examination revealed mild problems in concentration and her performance was slow, however at that point the neuropsychological profile was not regarded supportive for a dementing disease. At the age of 55 years, she was again referred to neurologist because of increasing memory problems.
Neuropsychological examination revealed a decline in episodic memory, time orientation, visual reasoning, and perception in addition to executive dysfunction. She also suffered from depression and psychosis. In neurological examination, she had intention tremor and her speech was uninhibited but otherwise the examination was normal. Brain MRI showed moderate hippocampal atrophy bilaterally and cortical atrophy especially in the temporobasal areas. The CSF biomarkers for AD were normal. The patient was diagnosed to have frontal variant of AD.
Four years after the diagnosis, the neuropsychological examination revealed severe cognitive decline, especially memory impairment, including major problems in delayed recall, working memory, learning and verbal memory in addition to executive dysfunction. The patient's mother got demented in her early fifties and her sister had been diagnosed to have AD at the age of 52 years. The patient also carried the UBQLN2 p. Ile501Thr variant. 
Discussion
In the present study, we have aimed at elucidating the genetic background of early-onset AD and FTLD cases. We found two previously reported pathogenic mutations in our cohort of EOD. The onset of the disease was under 55 years and both patients had a positive family history of neurodegenerative diseases. The PSEN1 p.His163Arg mutation has been found in over 20 families worldwide so far [19] . PSEN1 mutations have commonly been associated with very early-onset AD with atypical clinical features [22, 23] . Interestingly, the location of the PSEN1 mutation appears to lead to differences in clinical manifestations. Patients with mutations before codon 200, such as the PSEN1 p.His163Arg mutation, usually show an early onset of the disease and more frequently display generalized seizures and myoclonus, all of which were also present in the patient of our study [24] . Interestingly, the patient also suffered from vocal tics. A few previously reported PSEN1 p.His163Arg mutation carriers have also had visual hallucinations and parkinsonism with rigidity and bradykinesia, but these symptoms were not observed in our patient [25] . However, the fact that the mother of the PSEN1 p.His163Arg mutation carrier had manifested parkinsonism and psychiatric symptoms suggests that she might have been a PSEN1 p.His163Arg mutation carrier as well.
The MAPT p.Arg406Trp mutation has been reported in over 60 patients so far [26] . Mutations in the MAPT gene are typically associated with tau pathology [26] . Despite the neuropathological findings typical for FTLD, the clinical phenotypes of the patients with the MAPT p.Arg406Trp mutation have suggested that they rather have AD than FTLD [26] .
Especially, amnestic cognitive decline has been the most frequent first symptom in patients carrying this mutation, leading to AD diagnosis in the majority of the cases [26] . This phenotype was also present in the patient of our study. In addition to cognitive decline, the patient suffered from behavioural problems and severe psychiatric symptoms. A few MAPT p.Arg406Trp mutation carriers have also shown parkinsonian symptoms, but these were not detected in our patient [27] . About half of the previously reported mutation carriers have had elevated levels of tau and phosphorylated tau in the CSF. However, in our patient, the CSF AD biomarkers were normal [26] . In previous cases, the median age at onset has been 55 years, which is in line with our case [26] .
We also detected a PSEN2 p.Arg71Trp mutation, the pathogenicity of which is unclear [20] . This mutation has been found both in late-onset AD (LOAD) and EOAD patients [28] [29] [30] [31] .
However, the facts that it did not appear to segregate with AD in the families of the carriers, nor did it affect the Aβ42/Aβ40 ratio in an in vitro assay, and it was also found in healthy controls suggest that it is likely a benign mutation [10, 20, 28] . Interestingly though, the brain biopsy of the patient in our study revealed AD-type neuropathology. There is also a previous report of severe AD-type neuropathological findings of one PSEN2 p.Arg71Trp mutation carrier, who had an early onset, but very slowly progressive AD [31] . Patients carrying the PSEN2 mutations have usually an onset of the disease around 60 years and the disease duration may be even 20 years further suggesting that this mutation associates with slow disease progression [24] . Allele frequency of the PSEN2 p.Arg71Trp in the Finnish population is low (0.0195 %, Table 1 ). However, since it has been found also in Finnish healthy controls, it has been suggested that alone this mutation is not likely sufficient to cause AD [10] . Nevertheless, PSEN2 p.Arg71Trp mutation might be a risk factor for AD or possibly even pathogenic with a slowly progressive course of the disease regarding that the frequency of the mutation has been reported to be higher in LOAD patients than in the general population [32] and it is possible that some of the healthy controls in the previous studies that were found to carry the PSEN2 p.Arg71Trp mutation might have developed AD later.
We also identified GRN p.Arg433Trp, PSEN1 p.Glu318Gly, MAPT p.Gln230Arg, and MAPT p.Tyr441His variants that have been suggested to be benign in previous studies [19] . PSEN1 p.Glu318Gly might be a risk factor for familial AD, but the results so far are controversial [33] .
Furthermore, we identified three variants, which have previously been described as possible risk variants for AD or FTLD and one variant with possible risk-reducing effect ( Table 1 ). The carrier of the TREM2 p.Arg62His variant had also APOE genotype E3/E4. TREM2 p.Arg62His has been reported as a possible risk factor for LOAD (OR 0.8-2.3) [34] and it has also been found in a few EOAD cases [12] . The interaction of the APOE4 allele and TREM2 has been suggested to accelerate the development of neurodegeneration [35] . The effects of the other identified possible risk variants have been less significant [36] [37] [38] [39] . The frequencies of these polymorphisms in our cohort did not differ from the population frequencies reported in the ExAC database. In any case, our cohort was too small to make any conclusions regarding the involvement of these variants in influencing the risk for dementia.
The key role of the C9orf72 repeat expansion has been well demonstrated in FTLD and its prevalence is high in Finland [5] [6] [7] . In this study we focused on to search for other pathogenic mutations and risk factors for AD and FTLD in the cohort of EOD patients of still unknown genetic background after exclusion of the C9orf72 repeat expansion. The strength of this study is that our cohort is clinically very well-characterized, and the patients have been thoroughly examined by experienced neurologists specialized in memory disorders, increasing the validity of our results.
In conclusion, we identified two pathogenic mutations in PSEN1 and MAPT genes in a Finnish EOD cohort. Both identified cases had a very early onset of the disease and a positive family history of dementia or psychiatric diseases. Even though autosomal dominant mutations are rare causes of dementia, our study suggests that it is worthwhile to screen for them in EOD patients, who show an onset age under 55 years and a positive family history. 
